Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.

Publication Year: 2022

DOI:
10.2147/OTT.S305429

PMCID:
PMC9327779

PMID:
35912273

Journal Information

Full Title: Onco Targets Ther

Abbreviation: Onco Targets Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors report no conflicts of interest in this work."

Evidence found in paper:

"This work was supported in part by the National Institutes of Health/National Institute of Aging grant R21-AG070502-01 (RLC). We also acknowledge the support by the Amyloidosis and Myeloma Research Fund at Tufts Medical Center, the Cam Neely and John Davis Myeloma Research Fund, the John C Davis Program for Myeloma and Amyloid at Tufts, the Sidewater Family Fund, the Lavonne Horowitz Trust, the Werner and Elaine Dannheisser Fund for Research on the Biology of Aging of the Lymphoma Foundation, David and Barbara Levine (in memoriam), and the Demarest Lloyd Jr Foundation."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025